|
Dr. Barnett is a successful drug development executive who brought four drugs to the marketplace during his tenure at Schering-Plough, two of which were blockbusters. His career was spent in Drug Discovery, where he led the effort that resulted in the discovery of Claritin, a non-sedating antihistamine that was Schering-Plough's leading product and the fifth leading drug, based on sales, in the world. Dr. Barnett managed a discovery program that led to Doral, a sedative-hypnotic that was out-licensed by Schering. Dr. Barnett and his colleagues made a major contribution to the field of dopamine receptors by discovering and developing the first D1 receptor antagonists. He managed the discovery program that led to Zetia, a novel cholesterol-lowering agent that was introduced to the market in November 2002, and to Clarinex, the successor to Claritin. In 1994, Dr. Barnett assumed the duties of Vice President of Technology Acquisition and External Collaborations with the objective of facilitating all areas of drug discovery based collaborations for SPRI.
Dr. Barnett is a graduate of Rutgers University and the University of Buffalo School of Medicine. He has authored or co-authored more than 100 scientific publications. | 